Development and Evaluation of Prediction Models for Breast Cancer Prognosis
Development and Evaluation of Prediction Models for Breast Cancer Prognosis
批准号:
8836985
负责人:
Fei Ye
金额:
$7.57万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-04-10 至 2016-04-29
关键词:
AdjuvantAgeAsian AmericansAsiansBody mass indexBreastBreast Cancer ModelBreast Cancer PatientBreast Cancer survivorCancer EtiologyCancer PatientCancer PrognosisCensusesCessation of lifeChinaClinicalClinical TrialsCohort StudiesCountryDataDecision MakingDevelopmentDiagnosisDisease-Free SurvivalEatingEpidermal Growth Factor ReceptorEstrogen Receptor StatusEstrogen ReceptorsEthnic OriginEthnic groupEvaluationFoundationsHealthHealth PersonnelHealth PolicyHigh Risk WomanHormone ReceptorHumanIndividualInterventionInvestigationKnowledgeLifeLife StyleMalignant NeoplasmsMeasuresMedical SurveillanceModelingObesityOutcomePatient CarePatientsPerformancePhysical activityPolicy DevelopmentsPopulationPrevalencePreventive InterventionProcessProgesterone Receptor StatusProgesterone ReceptorsPrognostic FactorProviderPublic HealthRaceRecurrenceRelative (related person)ReportingResearchResourcesRiskSoy FoodsSubgroupSurvival RateToxic effectTreatment EfficacyUnited KingdomWeight GainWomanbasecancer diagnosiscancer riskclinical predictorscostdata registryempoweredimprovedindividualized medicinelifestyle factorslymph nodesmalignant breast neoplasmnoveloutcome forecastpersonalized medicinepopulation basedpredictive modelingprogramsprospectiverapid growthtooltumoryoung woman
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): One in eight US women will be diagnosed with breast cancer during her lifetime, making it the second leading cause of cancer deaths among US women. Currently, there are about 3.1 million women living with breast cancer in the US. Despite the overall favorable prognosis for breast cancer, the risk of recurrence persists for the remainder of the patient's lifetime, with a 15-year recurrence rate greater than 40%. Accurate prediction of breast cancer outcomes, therefore, is essential for developing personalized treatment, which would maximize treatment efficacy, spare patients unnecessary treatment, and identify women at high risk of recurrence for preventive intervention. However, existing prediction tools and models for breast cancer prognosis, including Adjuvant! online, the most widely used prediction tool in the US, include only clinicopathological prognostic factors (e.g., age, tumor grade and size, and lymph node, hormone receptor , and estrogen receptor status), without considering well-recognized lifestyle predictors such as obesity, weight gain, and post-diagnosis physical activity. In addition, no prediction tool or models have been developed and validated among Asian women with breast cancer. In the proposed study, we will utilize the resources of the Shanghai Breast Cancer Survival Study, a well characterized, population-based prospective cohort study of 5,042 breast cancer survivors with detailed information on lifestyle factors, to build prediction models that incorporate both clinicopathological and lifestye factors. Separate prediction models will be built first for 5-and 10-year overall survival, breast cancer-specific survival, and disease-free survival based on the clinicopathological factors that are included in Adjuvant! online, and then expanded to incorporate lifestyle factors. Models will be validated and evaluated for predictive ability, then compared with existing breast cancer prediction tools/models. The proposed study is cost-efficient, feasible, and will fill gaps in breat cancer outcomes prediction research. While the prevalence of lifestyle factors may differ between the US and China, we have specifically demonstrated this in our investigations of lifestyle factors and breast cancer outcomes in several large-scale studies that physical activity,
pre-diagnosis BMI, and soy food intake, are associated with breast cancer outcomes, regardless of country or race/ethnicity. Therefore, the knowledge gained from the proposed study should be generalizable for building prediction models for breast cancer patients of other racial and ethnic groups.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development and Evaluation of Prediction Models for Breast Cancer Prognosis
-
批准号:8702691
-
项目类别:
-
资助金额:$7.84万
-
财政年份:2014
-
负责人:Fei Ye
-
依托单位:
Development and Evaluation of Prediction Models for Breast Cancer Prognosis
-
批准号:9320086
-
项目类别:
-
资助金额:$0.28万
-
财政年份:2014
-
负责人:Fei Ye
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: